- $8.56bn
- $10.12bn
- $2.55bn
- 78
- 46
- 65
- 67
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 2,601 | 1,781 | 3,580 | 5,335 | 2,553 |
Cost of Revenue | |||||
Gross Profit | 2,067 | 1,476 | 3,109 | 4,789 | 2,254 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 4,820 | 2,624 | 2,302 | 2,568 | 2,151 |
Operating Profit | -2,219 | -843 | 1,279 | 2,767 | 403 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -2,217 | -737 | 402 | 1,414 | 1,100 |
Provision for Income Taxes | |||||
Net Income After Taxes | -1,716 | -712 | 412 | 1,183 | 871 |
Net Income Before Extraordinary Items | |||||
Net Income | -1,716 | -712 | 412 | 1,183 | 871 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | -1,717 | -712 | 401 | 1,155 | 856 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.722 | -1.55 | 1.68 | 5.26 | 4.05 |
Dividends per Share |